Scarica l'app Stockscreener
42.33
0.55%
0.23
Dopo l'orario di chiusura:
42.32
-0.010
-0.02%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MLTX Giù?
Forum
Previsione
Moonlake Immunotherapeutics Borsa (MLTX) Ultime notizie
Congress Asset Management Co. Boosts Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Rice Hall James & Associates LLC Raises Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Will MoonLake Immunotherapeutics Lead Healthcare Stocks’ Resurgence? - DSA
Why MoonLake Immunotherapeutics Could Be the Next Big Bet in Healthcare - MotoPaddock
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now - Yahoo Finance
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
(MLTX) Proactive Strategies - Stock Traders Daily
What is Leerink Partnrs' Forecast for MLTX FY2025 Earnings? - MarketBeat
We're Hopeful That MoonLake Immunotherapeutics (NASDAQ:MLTX) Will Use Its Cash Wisely - Yahoo Finance
Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
JPMorgan Chase & Co. Has $62,000 Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
(MLTX) Trading Report - Stock Traders Daily
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
JPMorgan Chase & Co. Reduces Stock Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Swiss company MoonLake leverages Cambridge in transformative year - Business Weekly
When the Price of (MLTX) Talks, People Listen - Stock Traders Daily
Cantor Fitzgerald Estimates MLTX FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on MLTX FY2025 Earnings - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Up 6.3%Still a Buy? - MarketBeat
Barclays PLC Purchases 5,229 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Comparing Petros Pharmaceuticals (NASDAQ:PTPI) & MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
Goldman Sachs raises target price for dermatological drug maker MoonLake by 32% - Kursiv Media
MoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap UpWhat's Next? - MarketBeat
MoonLake upgraded at Goldman Sachs on promise of hidradenitis suppurativa asset - MSN
MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon - Seeking Alpha
Goldman Sachs Upgrades MoonLake Immunotherapeutics (MLTX) - MSN
This little-known biotech stock is a buy that’s primed to double in price, Goldman says - thepress.net
MoonLake Immunotherapeutics (NASDAQ:MLTX) Raised to Buy at The Goldman Sachs Group - MarketBeat
MoonLake Immunotherapeutics Sees Stock Target Shifts - TipRanks
How the (MLTX) price action is used to our Advantage - Stock Traders Daily
HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX) - Defense World
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Brokerages Set MoonLake Immunotherapeutics (NASDAQ:MLTX) PT at $81.43 - MarketBeat
MoonLake Immunotherapeutics initiates three new clinical trials - TipRanks
MLTX Crosses Below Key Moving Average Level - Nasdaq
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
MoonLake Immunotherapeutics price target raised to $81 from $71 at BTIG - Yahoo Finance
MoonLake initiates three new clinical trials and further - GlobeNewswire
MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab - Finansavisen
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):